5,286 Shares in Insulet Corporation $PODD Bought by Cibc World Market Inc.

Cibc World Market Inc. purchased a new position in Insulet Corporation (NASDAQ:PODD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,286 shares of the medical instruments supplier’s stock, valued at approximately $1,502,000.

Other large investors also recently bought and sold shares of the company. Larson Financial Group LLC increased its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter worth $28,000. Fideuram Asset Management Ireland dac bought a new position in Insulet during the fourth quarter valued at $41,000. Measured Wealth Private Client Group LLC bought a new position in Insulet during the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet during the second quarter valued at $51,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PODD. Barclays cut their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research report on Thursday, May 7th. Citigroup cut their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Oppenheimer cut their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Evercore cut their price objective on shares of Insulet from $240.00 to $200.00 in a research report on Thursday, May 7th. Finally, Raymond James Financial set a $216.00 price objective on shares of Insulet in a research report on Monday. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $250.00.

Insider Activity

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.36% of the company’s stock.

Insulet Stock Up 5.3%

Shares of PODD opened at $159.61 on Wednesday. The firm has a market capitalization of $11.05 billion, a P/E ratio of 37.12, a P/E/G ratio of 1.19 and a beta of 1.13. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a fifty day moving average price of $173.43 and a 200-day moving average price of $235.68.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.